Lorundrostat Shows Promise in Phase 2 Trial for Uncontrolled, Resistant Hypertension
New data from a dose-finding trial suggests the aldosterone synthase inhibitor lorundrostat could find a role in the management of resistant or uncontrolled hypertension.